Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084914 | 0.86 | MCL1 (0.57) | MCL1 | |
| SCHEMBL418126 | 0.86 | MCL1 (1.00) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3534182 | 0.85 | MCL1 (0.73) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10084917 | 0.82 | MCL1 (0.69) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31435640 | 0.82 | MCL1 (0.69) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1096760 | 0.82 | L3MBTL1 (0.70) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15219890 | 0.81 | MCL1 (0.55) | MCL1 | |
| SCHEMBL10084910 | 0.81 | CLK1 (0.63) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL18554862 | 0.80 | MCL1 (0.54) | MCL1 | |
| SCHEMBL2732524 | 0.79 | KDM4E (0.76) | MCL1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | MCL1 596/4885KDM4E 4720/4885ALDH1A1 1099/4885 |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | MCL1 305/4885KDM4E 4305/4885ALDH1A1 3792/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | MCL1 596/4885KDM4E 4720/4885ALDH1A1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.